Neurosense Therapeutics is trading at $3.10, up +32.48% in after-hours trading; no verified company-specific catalyst was identified for October 20, 2026.
- The latest identified company news was an October 19 patent application for PrimeC in traumatic brain injury, but available sources do not establish it as the reason for the rise.
- Major U.S. indexes closed higher, though that broad market context does not clearly explain the stock’s sharp move. Trading volume and activity details were unavailable in the supplied price context and reviewed company news.